BioMarin Pharmaceutical Inc

詳細情報 BioMarin Pharmaceutical Inc 企業名

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

企業情報

企業コードBMRN

会社名BioMarin Pharmaceutical Inc

上場日Jul 23, 1999

最高経営責任者「CEO」Mr. Alexander Hardy

従業員数3040

証券種類Ordinary Share

決算期末Jul 23

本社所在地770 Lindaro Street

都市SAN RAFAEL

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号94901

電話番号14155066700

ウェブサイトhttps://www.biomarin.com/

企業コードBMRN

上場日Jul 23, 1999

最高経営責任者「CEO」Mr. Alexander Hardy

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+5.85%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

62.99K

-53.04%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

46.81K

+61.08%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+21.80%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-7.36%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+39.97%

Dr. Athena M. Countouriotis, M.D.

Independent Director

8.83K

+305.05%

Ms. Barbara W. Bodem

Independent Director

8.83K

+305.05%

Ms. Elizabeth Mckey Anderson

Independent Director

--

Mr. Timothy Walbert

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Richard A. (Randy) Meier

Non-Executive Independent Chairman of the Board

120.34K

+5.85%

Mr. Alexander Hardy

President, Chief Executive Officer, Director

62.99K

-53.04%

Dr. Gregory R Friberg, M.D.

Executive Vice President, Chief Research & Development Officer

46.81K

+61.08%

Mr. Robert J. (Bob) Hombach, CPA

Independent Director

37.15K

+21.80%

Ms. Cristin Hubbard

Executive Vice President, Chief Commercial Officer

30.55K

-7.36%

Dr. Maykin Ho, Ph.D.

Independent Director

23.29K

+39.97%

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

事業別USD

会社名

収益

比率

Voxzogo

213.75M

29.10%

Vimizim

188.35M

25.64%

Naglazyme

114.29M

15.56%

Palynziq

93.27M

12.70%

Aldurazyme

48.98M

6.67%

他の

76.01M

10.35%

地域別USD

会社名

収益

比率

United States

241.69M

32.90%

Europe

229.58M

31.25%

Rest of the world

126.11M

17.17%

Latin America

88.28M

12.02%

ALDURAZYME net product revenues marked by Sanofi

48.98M

6.67%

事業別

地域別

事業別USD

会社名

収益

比率

Voxzogo

213.75M

29.10%

Vimizim

188.35M

25.64%

Naglazyme

114.29M

15.56%

Palynziq

93.27M

12.70%

Aldurazyme

48.98M

6.67%

他の

76.01M

10.35%

株主

更新時刻: Sat, Aug 16

株主統計

種類

株主統計

比率

The Vanguard Group, Inc.

9.85%

BlackRock Institutional Trust Company, N.A.

9.39%

PRIMECAP Management Company

8.21%

Dodge & Cox

7.87%

Viking Global Investors LP

6.40%

他の

58.27%

株主統計

比率

The Vanguard Group, Inc.

9.85%

BlackRock Institutional Trust Company, N.A.

9.39%

PRIMECAP Management Company

8.21%

Dodge & Cox

7.87%

Viking Global Investors LP

6.40%

他の

58.27%

種類

株主統計

比率

Investment Advisor

43.86%

Investment Advisor/Hedge Fund

39.63%

Hedge Fund

7.66%

Pension Fund

3.19%

Research Firm

1.70%

Sovereign Wealth Fund

1.23%

Bank and Trust

1.17%

Individual Investor

0.75%

Venture Capital

0.34%

他の

0.47%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

1333

195.10M

101.61%

-16.01M

2025Q1

1355

191.53M

99.87%

-20.72M

2024Q4

1336

190.53M

99.88%

-17.50M

2024Q3

1308

188.26M

98.81%

-22.17M

2024Q2

1293

192.58M

101.18%

-14.21M

2024Q1

1278

194.24M

102.38%

-11.23M

2023Q4

1294

193.16M

102.42%

-3.22M

2023Q3

1275

188.66M

100.18%

-4.68M

2023Q2

1283

185.80M

98.76%

-8.08M

2023Q1

1274

186.38M

99.36%

-9.64M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

18.92M

9.87%

-369.57K

-1.92%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

18.12M

9.45%

-16.94K

-0.09%

Mar 31, 2025

PRIMECAP Management Company

17.77M

9.27%

-415.89K

-2.29%

Mar 31, 2025

Dodge & Cox

14.96M

7.8%

+209.00K

+1.42%

Mar 31, 2025

Viking Global Investors LP

10.80M

5.63%

+289.51K

+2.75%

Mar 31, 2025

State Street Global Advisors (US)

8.46M

4.41%

-649.18K

-7.12%

Mar 31, 2025

AQR Capital Management, LLC

2.93M

1.53%

+1.64M

+127.94%

Mar 31, 2025

Geode Capital Management, L.L.C.

3.43M

1.79%

+142.47K

+4.33%

Mar 31, 2025

Norges Bank Investment Management (NBIM)

3.57M

1.86%

-49.67K

-1.37%

Dec 31, 2024

詳細を見る

55.140USD

BioMarin Pharmaceutical Inc

55.140

概要

企業名

金融

分析